Last reviewed · How we verify
GSK2269557 DPI
At a glance
| Generic name | GSK2269557 DPI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Absorption & Elimination of Radiolabelled GSK2269557 (PHASE1)
- Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects (PHASE1)
- A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma (PHASE2)
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects (PHASE1)
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2269557 DPI CI brief — competitive landscape report
- GSK2269557 DPI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI